Stockreport

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com
PDF - Data supportive of CX-801's mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA ® (pembrolizumab) - SOUTH SAN FRANCISCO, Calif., Nov. 04, 20 [Read more]